Pharma Industry Urges HTA Bodies To Look Beyond Survival Data For Cancer Drugs
Executive Summary
A new report by industry association EFPIA says that health technology assessment bodies often rely too heavily on overall survival data when assessing the value of novel cancer drugs, and should take into account other clinical and patient-reported outcome measures where appropriate.
You may also be interested in...
How Useful Are Surrogate Endpoints In Securing Reimbursement Of Cancer Drugs?
A group of Australian researchers says that the use of surrogate outcomes needs to be better justified if health technology assessment bodies are to make more consistent funding decisions for cancer medicines.
Patient Voice Makes Impact In Scientific Advice From EU HTA Network
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Immuno-oncology Drugs And The Trouble With Market Access
The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data, broad labels and cost all contributing to disparate reimbursement decisions.